Loading
A phase 2 trial of Botensilimab in colorectal cancer, run by Agenus Inc., active and no longer recruiting.
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer is a phase 2 interventional study registered as NCT05608044 by Agenus Inc., with 234 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2027-09. Interventions recorded: Botensilimab, Balstilimab, Standard of Care. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab, Colorectal cancer.
Shares Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Hot vs cold tumours.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/